Akeso Biomedical Enters into License Agreement for Fe3C Compounds to Prevent Foodborne Illness

Akeso Biomedical Enters into License Agreement for Fe3C Compounds to Prevent Foodborne Illness
Waltham, MA (PRWEB) May 12, 2015 Akeso Biomedical, Inc., a privately held company developing new solutions for the treatment of bacterial infections and microbial biofilms, announced that it has exclusively licensed a new class of compounds designed to treat bacterial infections. The new class of compounds, known as Fe3C, has broad-spectrum activity against a wide ...